Exelixis
EXEL
#1680
Rank
NZ$17.37 B
Marketcap
$60.83
Share price
2.24%
Change (1 day)
69.73%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : NZ$1.16 Billion

According to Exelixis's latest financial reports the company's total liabilities are NZ$1.16 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31NZ$1.07 B16.82%
2022-12-31NZ$0.91 B54.64%
2021-12-31NZ$0.59 B65.94%
2020-12-31NZ$0.35 B20.69%
2019-12-31NZ$0.29 B47.51%
2018-12-31NZ$0.20 B-61.45%
2017-12-31NZ$0.52 B-28.68%
2016-12-31NZ$0.73 B5.75%
2015-12-31NZ$0.69 B23.64%
2014-12-31NZ$0.55 B5.13%
2013-12-31NZ$0.53 B3.03%
2012-12-31NZ$0.51 B33.13%
2011-12-31NZ$0.38 B-49.22%
2010-12-31NZ$0.76 B9.36%
2009-12-31NZ$0.69 B-11.51%
2008-12-31NZ$0.78 B85.05%
2007-12-31NZ$0.42 B-1.45%
2006-12-31NZ$0.43 B7.37%
2005-12-31NZ$0.40 B19.47%
2004-12-31NZ$0.33 B11.68%
2003-12-31NZ$0.30 B-3.15%
2002-12-31NZ$0.31 B18.37%
2001-12-31NZ$0.26 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
NZ$101.95 B 8,614.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$103.93 B 8,784.15%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$124.65 B 10,555.07%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$130.63 B 11,065.83%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$142.39 B 12,071.30%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$184.71 B 15,688.55%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$216.81 B 18,432.04%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$87.3 M-92.54%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.12 B-89.43%๐Ÿ‡บ๐Ÿ‡ธ USA